445680 — Curiox BioSystems Co Cashflow Statement
0.000.00%
- KR₩378bn
- KR₩358bn
- KR₩5bn
Annual cashflow statement for Curiox BioSystems Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | — | -14,525 | -11,498 | -10,042 | -8,089 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | — | 7,904 | 682 | -487 | -4,228 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2,661 | 260 | -671 | 413 | 500 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -2,661 | -5,126 | -9,888 | -8,164 | -9,698 |
Capital Expenditures | -188 | -261 | -841 | -212 | -258 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 2,293 | -8,050 | 5,574 | 3,110 | -4,017 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 2,105 | -8,311 | 4,734 | 2,898 | -4,275 |
Financing Cash Flow Items | — | 13,087 | — | — | -29.9 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 97.5 | 16,999 | -237 | 17,644 | 19,861 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -645 | 3,960 | -5,407 | 12,312 | 6,279 |